Poly(ADP-ribose) polymerase inhibitors (PARPis) have been associated with an increased incidence of MDS/AML, particularly in patients harboring TP53 CH mutations and often with a short latency after initial exposure [34]. This evidence concerns the gene TP53 and acute myeloid leukemia.